J&J’s Actelion, Nippon Sue to Block Copies of Uptravi Lung Drug

April 9, 2020, 10:23 PM

J&J’s Actelion unit and Nippon Shinyaku said proposed generic versions of a treatment for high blood pressure in arteries linking the heart and the lungs by Alembic and other companies infringe as many as three patents for Uptravi.

  • Uptravi is used to treat the rare and potentially deadly disease
  • J&J seeks court orders blocking copies until the patents have expired, and to collect cash compensation if copies are made before then, according to a complaint filed Thursday in federal court in Newark, New Jersey
  • Patents expire in April 2023 and in June and August 2030: FDA Orange Book
  • J&J ...

To read the full article log in.

Learn more about A Bloomberg Law subscription.